AKT1 and diffuse large B-cell lymphoma: Severalgenetic variations are on the basis of cellular resistance to ibrutinibin B-cell cancers such as DLBCL,44 includingthe missense cysteine-to-serine mutation at position 481 in BTK, andthe compensatory upregulation of the PI3K/AKT signaling pathway.